TARO-TESTOSTERONE GEL
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
19-10-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
TESTOSTERONE
Tillgänglig från:
TARO PHARMACEUTICALS INC
ATC-kod:
G03BA03
INN (International namn):
TESTOSTERONE
Dos:
1%
Läkemedelsform:
GEL
Sammansättning:
TESTOSTERONE 1%
Administreringssätt:
TRANSDERMAL
Enheter i paketet:
5GX30
Receptbelagda typ:
Schedule G (CDSA IV)
Terapiområde:
ANDROGENS
Produktsammanfattning:
Active ingredient group (AIG) number: 0106405004; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2017-05-05
Produktens egenskaper
Page 1 of 39
PRODUCT MONOGRAPH
TARO-TESTOSTERONE GEL
TESTOSTERONE GEL
1% W/W
ANDROGENS
FOR TOPICAL USE ONLY
Taro Pharmaceuticals Inc.
130 East Brampton,
Ontario L6T 1C1
Submission Control No: 243359 Date of Preparation: October 19, 2020
Page 2 of 39
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
.....................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE
REACTIONS....................................................................................................
11
DRUG INTERACTIONS
....................................................................................................
18
DOSAGE AND ADMINISTRATION
................................................................................
19
OVERDOSAGE
..................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
.............................................................. 21
STORAGE AND STABILITY
............................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
.........................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 24
PART II: SCIENTIFIC INFORMATION
..................................................................................
26
PHARMACEUTICAL INFORMATION
............................................................................
26
CLINICAL TRIALS
........................................................................................
Läs hela dokumentet
